Sign in
4

Changes in Ownership

Amylyx Pharmaceuticals, Inc. Filed Acc 0001193125-26-458247

Chief Financial Officer sold 40,000 shares at an average $30.19 ($1,207,742)

  • Chief Financial Officer acquired 40,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
FRATES JAMES M Chief Financial Officer 2026-11-09 Option exercise 10b5-1 +20,000 $6.88 $137,600 253,625 D
FRATES JAMES M Chief Financial Officer 2026-11-09 Sale 10b5-1 −7,700 $29.39 $226,293 245,925 D
FRATES JAMES M Chief Financial Officer 2026-11-09 Sale 10b5-1 −12,300 $30.11 $370,359 233,625 D
FRATES JAMES M Chief Financial Officer 2026-11-10 Option exercise 10b5-1 +20,000 $6.88 $137,600 253,625 D
FRATES JAMES M Chief Financial Officer 2026-11-10 Sale 10b5-1 −12,800 $30.32 $388,108 240,825 D
FRATES JAMES M Chief Financial Officer 2026-11-10 Sale 10b5-1 −7,200 $30.97 $222,983 233,625 D
Derivatives
FRATES JAMES M Chief Financial Officer 2026-11-09 Option exercise · Stock Option (right to buy) 10b5-1 −20,000 343,835 D
FRATES JAMES M Chief Financial Officer 2026-11-10 Option exercise · Stock Option (right to buy) 10b5-1 −20,000 323,835 D
Open-market sales · 40,000 sh · avg $30.19 · $1,207,742
Loading xslF345X06/ownership.xml…